COVID-19 may trigger or worsen refractory, or difficult-to-treat, thrombotic thrombocytopenic purpura (TTP) during the first months of pregnancy, requiring early diagnosis and aggressive treatment…
Thrombotic thrombocytopenic purpura
The preventive treatment Adzynma (recombinant human ADAMTS13) is safe and effective at reducing disease relapses for people with congenital thrombotic thrombocytopenic purpura (TTP), and…
A combination of blood biomarkers can help predict the short-term risk of death for people admitted to the hospital with thrombotic thrombocytopenic purpura (TTP),…
Levels of anti-ADAMTS13 antibodies measured after therapeutic plasma exchange (TPE) are associated with the time it takes to achieve normalization of ADAMTS13 activity in people…
Using both corticosteroids and plasma exchange therapy — each a standard treatment for acquired thrombotic thrombocytopenic purpura (TTP) — together was found to significantly…
The congenital form of thrombotic thrombocytopenic purpura (TTP) can look very different in one person than in another, but preventive treatment can help reduce…
A woman in Spain delivered a full-term, healthy baby after she was identified early as having congenital thrombotic thrombocytopenic purpura (TTP) and treated successfully…
People with immune-mediated thrombotic thrombocytopenic purpura (iTTP) who also have systemic lupus erythematosus (SLE) — have different symptoms and longer periods without disease relapse…
Platelet transfusions more than double the risk of death among people with thrombotic thrombocytopenic purpura (TTP), according to a review of published studies.
There appears to be no link between high blood pressure in the first two days after an acute episode of thrombotic thrombocytopenic purpura (TTP)…
